The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.

This week in oncology has been marked by significant strides in targeted therapies, a re-evaluation of established treatment paradigms, and compelling evidence for the impact of lifestyle ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

BAMF Health in Grand Rapids has launched a study to identify markers for targeted breast cancer therapies using PET scans.

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a ...